Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients
Tirzepatide, an obesity drug of Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Tirzepatide, an obesity drug of Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.
HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.
HQ team January 6, 2024: Eli Lilly, the pharmaceutical company will now be selling its weightless drug directly to the consumer via its.
HQ team November 28, 2023: A recent comparative analysis of Eli Lilly and Novo Nordisk’s weight loss drugs on diabetes patients showed Eli.